AbbVie (ABBV) Intangibles (2012 - 2026)
AbbVie (ABBV) reported Intangibles of $50.9 billion for Q1 2026, down 13.02% year-over-year from $58.5 billion in Q1 2025, and down 3.36% quarter-over-quarter from $52.6 billion in Q4 2025.
AbbVie (ABBV) Intangibles (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Intangibles data on file, last reported at $50.9 billion in Q1 2026.
- Intangibles for Q1 2026 came in at $50.9 billion, down 13.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.9 billion (down 13.02% YoY), and the FY2025 annual result was $52.6 billion, down 12.36% from the prior year.
- Intangibles declined to $50.9 billion in Q1 2026 per ABBV's latest filing, from $52.6 billion in the prior quarter.
- Over five years, Intangibles peaked at $74.0 billion in Q1 2022 and troughed at $711.0 million in Q3 2025.
- A 5-year average of $58.4 billion and a median of $60.2 billion in 2024 frame the typical range for Intangibles.
- The sharpest annual moves came in 2024 and 2025: Intangibles grew 13.72% in 2024, then plunged 98.93% in 2025.
- A 5-year view of Intangibles shows it stood at $67.4 billion in 2022, then dropped by 17.54% to $55.6 billion in 2023, then grew by 8.02% to $60.1 billion in 2024, then slipped by 12.36% to $52.6 billion in 2025, then fell by 3.36% to $50.9 billion in 2026.
- Business Quant data shows ABBV's Intangibles at $50.9 billion in Q1 2026, $52.6 billion in Q4 2025, and $711.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 24.45 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 7.37 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 49.06 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 50.87 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 18.24 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | 10.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.87 Bn |
| Dec 31, 2025 | 52.64 Bn |
| Sep 30, 2025 | 711.00 Mn |
| Jun 30, 2025 | 57.03 Bn |
| Mar 31, 2025 | 58.49 Bn |
| Dec 31, 2024 | 60.07 Bn |
| Sep 30, 2024 | 66.65 Bn |
| Jun 30, 2024 | 60.24 Bn |
| Mar 31, 2024 | 62.23 Bn |
| Dec 31, 2023 | 55.61 Bn |
| Sep 30, 2023 | 58.60 Bn |
| Jun 30, 2023 | 62.86 Bn |
| Mar 31, 2023 | 64.85 Bn |
| Dec 31, 2022 | 67.44 Bn |
| Sep 30, 2022 | 68.73 Bn |
| Jun 30, 2022 | 71.82 Bn |
| Mar 31, 2022 | 73.99 Bn |
| Dec 31, 2021 | 75.95 Bn |
| Sep 30, 2021 | 77.46 Bn |
| Jun 30, 2021 | 79.34 Bn |